Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice

Fig. 3

Effect of long-term linagliptin administration on body weight (a), blood sugar (b), oral glucose tolerance test (c), blood sugar area under curve (AUC) during OGTT (d), serum DPP-4 activity (e), serum GLP-1 (f), brain DPP-4 activity (g), and brain GLP-1 (h) in db/db mice subjected to transient BCCAO. OGTT in (c) and (d) were performed after 6 weeks of linagliptin administration. In (e), the mean value of sham group was expressed as 100 %. Abbreviations used: Sham, sham-operated group; BCCAO + Veh, group subjected to transient BCCAO followed by vehicle administration; BCCAO + Lin, group subjected to transient BCCAO followed by linagliptin administration; AUC, area under curve; NS, not significant between groups. Each value represents mean ± SEM. In (a)-(d), n = 10 in Sham, n = 10 in BCCAO + Veh, n = 11 in BCCAO + Lin. In (e) and (f), n = 9 in Sham, n = 5 in BCCAO + Veh, n = 7 in BCCAO + Lin. In (g) and (h), n = 10 in Sham, n = 9 in BCCAO + Veh, n = 11 in BCCAO + Lin

Back to article page